

# Literatura ACTA MEDICINAE

## 5–7/2021 Gynekologie | Onkogynekologie | Urologie

- 2 **Paliativní léčba pacientů s pokročilým hormonálně dependentním karcinomem prostaty**  
prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň
- 2 **Cílená léčba ovariálního karcinomu**  
prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 2 **Nemetastatický kastročně refrakterní karcinom prostaty**  
MUDr. Michaela Matoušková Urocentrum Praha, Onkologická klinika FTN a 1. LF UK, Praha
- 2 **Co vše zohledňujeme při hledání odpovědi na otázku pacientů, jak žít s vědomím „mám nádorové onemocnění“**  
prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno  
PhDr. Mgr. Jeroným Klimeš, Ph.D. Soukromá psychologická ambulance Praha 9 – Újezd nad Lesy  
doc. MUDr. Zdeněk Boleloucký, CSc. Psychiatrická klinika LF MU a FN Brno  
MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení Vsetínské nemocnice  
prof. MUDr. Luděk Pour, Ph.D. | prof. MUDr. Marta Krejčí, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno
- 3 **Hluboká endometrióza a její léčba**  
MUDr. Peter Koliba Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 3 **Choroby štítné žlázy v graviditě**  
MUDr. Kristýna Žabková | MUDr. Jan Krátký, Ph.D. | doc. MUDr. Jan Jiskra, Ph.D. III. interní klinika VFN a 1. LF UK, Praha
- 4 **Diagnostika a prevence preeklampsie**  
MUDr. Anna Jouzová | MUDr. Lukáš Hruban, Ph.D. Gynekologicko-porodnická klinika LF MU a FN Brno
- 4 **SiderAL Folic – lékový profil**  
MUDr. Peter Koliba Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 5 **Angusta – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 5 **Perorální misoprostol k indukci porodu. Komentář k článku Angusta – lékový profil**  
MUDr. Jan Matěcha Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 5 **Léčba mykotických infekcí v gynekologii**  
doc. MUDr. Petr Hamal, Ph.D. | MDDr. Lucie Svobodová Ústav mikrobiologie LF UP a Fakultní nemocnice Olomouc
- 5 **Teriparatid v léčbě osteoporózy i ostatních skeletálních onemocnění a komplikací**  
doc. MUDr. Václav Vyskočil, Ph.D. II. interní klinika – Osteocentrum, Klinika ortopedie a traumatologie pohybového ústrojí – Traumacentrum, FN Plzeň a LF UK, Plzeň
- 6 **Histiocytóza z Langerhansových buněk je imitátorkou četných jiných chorob. Klinické obrazy, diagnostika a přehled léčebných postupů v roce 2021**  
prof. MUDr. Zdeněk Adam, CSc. Interní hematoonkologická klinika LF MU a FN Brno  
MUDr. Marta Ježová, Ph.D. Patologický ústav LF MU a FN Brno  
MUDr. Tomáš Nebeský, CSc. Radiologická klinika LF MU a FN Brno  
doc. MUDr. Zdeněk Řehák, Ph.D. | MUDr. Renata Koukalová PET CT oddělení, Masarykův onkologický ústav, Brno  
MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení Vsetínské nemocnice  
prof. MUDr. Luděk Pour, Ph.D. | prof. MUDr. Marta Krejčí, Ph.D. | MUDr. Martin Štork, Ph.D. Interní hematoonkologická klinika LF MU a FN Brno

# Paliativní léčba pacientů s pokročilým hormonálně dependentním karcinomem prostaty

prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

1 www.sukl.cz  
2 www.links.cz

3 www.svod.cz  
4 www.uroweb.cz

## Cílená léčba ovariálního karcinomu

prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- Oza, A. M. – Cook, A. D. – Pfisterer, J., et al.: ICON7 trial investigators: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol*, 2015, 16, s. 928–936.
- Aghajanian, C. – Goff, B. – Nycum, L. R., et al.: Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. *Gynecol Oncol*, 2015, 139, s. 10–16.
- Poveda, A. M. – Selle, F. – Hilpert, F., et al.: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. *J Clin Oncol*, 2015, 33, s. 3836–3838.
- Pfisterer, J. – Plante, M. – Vergote, I., et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol*, 2006, 24, s. 4699–4707.
- Burger, R. A. – Sill, M. W. – Monk, B. J., et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. *J Clin Oncol*, 2007, 28, s. 5156–5171.
- Cannistra, S. A. – Matulonis, U. A. – Penson, R. T., et al.: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. *J Clin Oncol*, 2007, 25, s. 5180–5186.
- Aghajanian, C. – Blank, S. V. – Goff, B. A., et al.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol*, 2012, 30, s. 2039–2045.
- Ledermann, J. – Harter, P. – Gourley, C., et al.: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 852–861.
- Ledermann, J. – Harter, P. – Gourley, C., et al.: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med*, 2012, 366, s. 1382–1392.
- Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. Multimediální podpora výuky klinických a zdravotnických oborů: Portál Lékařské fakulty Masarykovy univerzity Dostupné z: <https://portal.med.muni.cz/clanek-583-epidemiologie-zhoubnych-nadoru-v-ceske-republice.html>, vyhledáno 18. 5. 2021.
- Moore, K. – Colombo, N. – Scambia, G., et al.: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*, 2018, 379, s. 2495–2505.
- Pujade-Lauraine, E. – Ledermann, J. A. – Selle, F., et al.: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 1274–1284.
- Mirza, M. R. – Monk, B. J. – Herrstedt, J., et al.: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med*, 2016, 375, s. 2154–2164.
- Berek, J. S. – Matulonis, U. A. – Peen, U., et al.: Safety and dose modification for patients receiving niraparib. *Ann Oncol*, 2018, 29, s. 1784–1792.
- Wang, J. – Zhang, Z.-Y. – Mirza, M. R., et al.: The exposure-response relationship of niraparib in patients with gBRCAmut and nonBRCAmut: results from the ENGOT-OV16/NOVA trial. *An Oncol*, 2017, 28, suppl. 5, s. v330–v354.
- Gonzalez, A. – Mirza, M. R. – Vergote, I., et al.: A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA study. *Ann Oncol*, 2018, 29, suppl. 8.
- Kristeleit, R. – Shapiro, G. I. – Burris, H. A., et al.: A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. *Clin Cancer Res*, 2017, 23, s. 4095–4106.
- Swisher, E. M. – Lin, K. K. – Oza, A. M., et al.: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 75–87.
- Oza, A. M. – Tinker, A. V. – Oaknin, A., et al.: Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. *Gynecol Oncol*, 2017, 147, s. 267–275.
- Coleman, R. L. – Oza, A. M. – Lorusso, D., et al.: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2017, 390, s. 1949–1961.
- González-Martín, A. – Pothuri, B. – Vergote, I., et al.: PRIMA/ENGOT-OV26/GOG-3012 Investigators: Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*, 2019, 381, s. 2391–2402.

## Nemetastický kastročně refraktérní karcinom prostaty

MUDr. Michaela Matoušková Urocentrum Praha, Onkologická klinika FTN a 1. LF UK, Praha

- Penson, D. F. – Armstrong, A. J. – Concepcion, R., et al.: Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. *J Clin Oncol*, 2016, 34, s. 2098–2106.
- Hussain, M. – Fizazi, K. – Saad, F., et al.: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2018, 378, s. 2465–2474.
- Fizazi, K. – Shore, N. – Tammela, T. L., et al.: Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2019, 380, s. 1235–1246.
- Smith, M. R. – Saad, F. – Chowdhury, S., et al.: SPARTAN Investigators: Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med*, 2018, 378, s. 1408–1418.
- Sternberg, C. N. – Fizazi, K. – Saad, F., et al.: PROSPER Investigators: Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2020, 382, s. 2197–2206.
- Fizazi, K. – Shore, N. – Tammela, T. L., et al.: ARAMIS Investigators: Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med*, 2020, 383, s. 1040–1049.
- Smith, M. R. – Saad, F. – Chowdhury, S., et al.: Apalutamide and overall survival in prostate cancer. *Eur Urol*, 2021, 79, s. 150–158.

## Co vše zohledňujeme při hledání odpovědi na otázku pacientů, jak žít s vědomím „mám nádorové onemocnění“

prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno

PhDr. Mgr. Jeroným Klimeš, Ph.D. Soukromá psychologická ambulance Praha 9 – Újezd nad Lesy

doc. MUDr. Zdeněk Boleloucký, CSc. Psychiatrická klinika LF MU a FN Brno

MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení Vsetínské nemocnice

prof. MUDr. Luděk Pour, Ph.D. | prof. MUDr. Marta Krejčí, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

- Klimeš, J.: *Křesťanství, vztahy a sex*. Praha, Novela Bohemica, 2016.
- Preiss, M. – Rothanzlová, S. – Krámská, L.: Odlišuje Cloningerův dotazník temperamentu a charakteru osoby s poruchou osobnosti a bez nich lépe než jiné dotazníkové metody? *Psychiatrie*, 2006, 10, s. 136–143.
- Preiss, M.: Cloningerova teorie temperamentu a charakteru a klinická praxe. *Psychiatrie*, 2000, 4, s. 43–45.
- Mravec, B. – Tibenský, M. – Horváthová, L.: Psychoneuroimmunologie nádorových chorob – současné východiska a perspektivy. *Klinická onkologie*, 2018, 31, s. 345–352.
- Adamová, Z. – Adam, Z.: Psychické vlivy na hojení ran. *Rozhl Chir*, 2019, 98, s. 312–314.
- Adamová, Z. – Adam, Z.: Psychologické aspekty v operační onkologii. *Rozhl Chir*, 2019, 98, s. 308–311.
- Kameníková, L. – Hučín, J.: Pozitivní emoce nám chrání zdraví. *Psychologie dnes*, 2004, 10, s. 1–3.
- Mareš, J. – Preiss, M. – Skourunka, D.: Pozitivní klinická psychologie. *Československá psychologie*, 2014, 58, s. 485–502.
- Seligman, M. E. P.: *Opravdové štěstí: pozitivní psychologie v praxi*. Praha, Ikar, 2003.
- Slezáčková, A.: *Průvodce pozitivní psychologií: nové přístupy, aktuální poznatky, praktické aplikace*. Praha, Grada, 2012.
- Slezáčková, A.: Sympóziem o pozitivní psychologii s M. Seligmanem. *Československá psychologie*, 2010, 54, s. 518–519.
- Slezáčková, A.: Pozitivní psychologie – věda nejen o štěstí. *E-psychologie*, 2010, 4, s. 55–70.
- Suchý, J. – Náhlovský, P.: *Pozitivní emoce: jak je posilovat a rozvíjet v osobním i pracovním životě*. Praha, Grada, 2012.
- Klimeš, J.: Dystymie – psychologická porucha s převážně negativním hodnocením všeho prožitého. Komentář psychologa. *Acta Medicae*, 2020, 10, s. 25–31.
- Mickley, J. R. – Cowles, K.: Ameliorating the tension: use of forgiveness for healing. *Oncol Nurs Forum*, 2001, 28, s. 31–37.
- Romero, C. – Friedman, L. C. – Kalidas, M., et al.: Self-forgiveness, spirituality, and psychological adjustment in women with breast cancer. *J Behav Med*, 2006, 29, s. 29–36.
- Toussaint, L. – Barry, M. – Angus, D., et al.: Self-forgiveness is associated with reduced psychological distress in cancer patients and unmatched caregivers: Hope and self-blame as mediating mechanisms.

- J Psychosoc Oncol*, 2017, 35, s. 544–560.
- Toussaint, L. – Barry, M. – Bornfriend, L., et al.: Restore: the journey toward self-forgiveness: a randomized trial of patient education on self-forgiveness in cancer patients and caregivers. *J Health Care Chaplain*, 2014, 20, s. 54–74.
  - Toussaint, L. – Worthington, E. L. Jr. – Van Tongeren, D. R., et al.: Forgiveness working: forgiveness, health, and productivity in the workplace. *Am J Health Promot*, 2018, 32, s. 59–67.
  - van Laarhoven, H. W. – Schilderman, J. – Verhagen, C. A., et al.: Comparison of attitudes of guilt and forgiveness in cancer patients without evidence of disease and advanced cancer patients in a palliative care setting. *Cancer Nurs*, 2012, 35, s. 483–492.
  - Bergenthal, N. – Will, A. – Streckmann, F., et al.: Aerobic physical exercise for adult patients with haematological malignancies. *Cochrane Database Syst Rev*, 2014, s. CD009075.
  - Courney, K. S. – Friedenreich, C. M. – Franco-Villalobos, C., et al.: Effects of supervised exercise on progression-free survival in lymphoma patients: an exploratory follow-up of the HELP Trial. *Cancer Causes Control*, 2015, 26, s. 269–276.
  - Hadrabová, M. – Janíková, A.: Význam fyzické aktivity pro přežití a kvalitu života u pacientů s lymfoproliferativním onemocněním. *Transfúze a hematologie dnes*, 2018, 3, s. 182–193.
  - Janíková, A. – Radvanský, J. – Vysoký, R., et al.: Význam fyzické aktivity u pacientů s hematologickými malignitami. *Transfúze a hematologie dnes*, 2012, 18, s. 31–38.
  - Kanamori, S. – Takamiya, T. – Inoue, S., et al.: Frequency and pattern of exercise and depression after two years in older Japanese adults: the JAGES longitudinal study. *Sci Rep*, 2018, 8, 11224, <https://doi.org/10.1038/s41598-018-29053-x>.
  - Knips, L. – Bergenthal, N. – Streckmann, F., et al.: Aerobic physical exercise for adult patients with haematological malignancies. *Cochrane Database Syst Rev*, 2019, 1, s. CD009075.
  - Moore, S. C. – Lee, I. M. – Weiderpass, E., et al.: Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. *JAMA Intern Med*, 2016, 176, s. 816–825.
  - Nebiker, L. – Lichtenstein, E. – Minghetti, A., et al.: Moderating effects of exercise duration and intensity in neuromuscular vs. endurance exercise interventions for the treatment of depression: a meta-analytical review. *Front Psychiatry*, 2018, 9, s. 305, doi: 10.3389/fpsy.2018.00305.
  - Pan, S. Y. – Morrison, H.: Physical activity and hematologic cancer prevention. *Recent Results Cancer Res*, 2011, 186, s. 135–158.
  - Persoon, S. – Chin, A. – Paw, M. J. M., et al.: Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study. *PLoS One*, 2017, 12, s. e0181313.
  - Rebar, R. A. – Stanton, R. – Geard, D., et al.: A meta-analysis of the effect of physical activity on depression and anxiety in non-clinical adult populations. *Health Psychology Review*, 2015, 9, s. 366–378.
  - Werneck, A. O. – Oyeyemi, A. L. – Silva, V. D.: Physical activity and depression: is 150 min/week of moderate to vigorous physical activity a necessary threshold for decreasing risk of depression in adults? Different views from the same data. *Soc Psychiatry Psychiatr Epidemiol*, 2018, 53, s. 323–324.
  - Looijaard, S. M. L. M. – Te Lintel Hekker, M. L. – Wüst, R. C. I., et al.: Pathophysiological mechanisms explaining poor clinical outcome of older cancer patients with low skeletal muscle mass. *Acta Physiol*, 2021, 231, s. e13516.
  - Sica, A. – Vitiello, P. – Ronchi, A., et al.: Primary cutaneous anaplastic large cell lymphoma (pcALCL) in the elderly and the importance of sport activity training. *Int J Environ Res Public Health*, 2020, 17, s. 839.
  - Adam, Z. – Klimeš, J. – Pour, R., et al.: *Maligní onemocnění, psychika a stres*. Praha, Grada, 2019.

## Hluboká endometrióza a její léčba

MUDr. Peter Koliba Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- Koninckx, P. R. – Martin, D. C.: Deep endometriosis: a consequence of infiltration or retraction or possibly adenomyosis externa? *Fertil Steril*, 1992, 58, s. 924–928.
- Koninckx, P. R. – Ussia, A. – Adamyan, L., et al.: Deep endometriosis: definition, diagnosis, and treatment. *Fertil Steril*, 2012, 98, s. 564–571.
- Indrielle-Kelly, T. – Frühauf, F. – Burgetová, A., et al.: Diagnosis of endometriosis 3<sup>rd</sup> part – Ultrasound diagnosis of deep endometriosis. *Ceska Gynekol*, 2019, 84, s. 269–275.
- De Pereira, L. B. – Braga, N. P. – Mendonca, M., et al.: Apoptosis of ectopic endometrial cells is impaired in women with endometriosis. *J Endometr Pelvic Pain Disord*, 2012, 4, s. 17–20.
- Machado, D. E. – Abrao, M. S. – Berardo, P. T., et al.: Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. *Fertil Steril*, 2008, 90, s. 148–155.
- Bazot, M. – Lafont, C. – Rouzier, R., et al.: Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. *Fertil Steril*, 2009, 92, s. 1825.
- Guerriero, S. – Condous, G. – Van Den Bosch, T., et al.: Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDeA) group. *Ultrasound Obstet Gynecol*, 2016, 48, s. 318–332.
- Keckstein, J. – Ulrich, U. – Possover, M., et al.: ENZIAN-Klassifikation der tief infiltrierenden Endometriose. *Zentralbl Gynäkol*, 2003, 125, s. 291.
- Keckstein, J. – Saridogan, E. – Ulrich, U. A., et al.: The #ENZIAN classification: A comprehensive non-invasive and surgical description system for endometriosis. *Acta Obstet Gynecol Scand*, 2021, 00, s. 1–11.
- Montanari, E. – Dauser, B. – Keckstein, J., et al.: Association between disease extent and pain symptoms in patients with deep infiltrating endometriosis. *G Reprod Biomed Online*, 2019, 39, s. 845–851.
- Vercellini, P. – Viganò, P. – Buggio, L., et al.: We can work it out: The hundred years' war between experts of surgical and medical treatment for symptomatic deep endometriosis. *J Minim Invasive Gynecol*, 2018, 25, s. 356–359.
- Ferrero, S. – Alessandri, F. – Racca, A., et al.: Treatment of pain associated with deep endometriosis: alternatives and evidence. *Fertil Steril*, 2015, 104, s. 771–792.
- Dunselman, G. A. J. – Vermeulen, N. – Becker, C., et al.: ESHRE guideline: management of women with endometriosis. *Hum Reprod*, 2014, 29, s. 400–412.
- Ferrero, S. – Camerini, G. – Ragni, N., et al.: Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. *Hum Reprod*, 2010, 25, s. 94–100.
- Leonardo-Pinto, J. P. – Benetti-Pinto, C. L. – Cursino, K., et al.: Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. *Eur J Obstet Gynecol Reprod Biol*, 2017, 211, s. 108–111.
- Yela, D. – Kajikawa, P. – Donati, L., et al.: Deep infiltrating endometriosis treatment with dienogest: a pilot study. *J Endometr Pelvic Pain Disord*, 2015, 7, s. 33–37.
- Fedele, L. – Bianchi, S. – Zanconato, G., et al.: Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. *Fertil Steril*, 2001, 75, s. 485–488.
- Casper, R. F.: Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. *Fertil Steril*, 2017, 107, s. 533–536.
- Fedele, L. – Bianchi, S. – Zanconato, G., et al.: Gonadotropin releasing hormone agonist treatment for endometriosis of the rectovaginal septum. *Am J Obstet Gynecol*, 2000, 183, s. 1462–1467.
- Roman, H. – Saint-Ghislain, M. – Milles, M., et al.: Improvement of digestive complaints in women with severe colorectal endometriosis benefiting from continuous amenorrhoea triggered by triptoreline. A prospective pilot study. *Gynecol Obstet Fertil*, 2015, 43, s. 575–581.
- Angioni, S. – Pontis, A. – Dessole, M., et al.: Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. Incomplete surgical treatment with or without GnRH-a administration after surgery. *Arch Gynecol Obstet*, 2015, 291, s. 363–370.
- DiVasta, A. D. – Feldman, H. A. – Sadler Gallagher, J., et al.: Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial. *Obstet Gynecol*, 2015, 126, s. 617–627.
- Chapron, C. – Chioldo, I. – Leconte, M., et al.: Severe ureteral endometriosis: the intrinsic type is not so rare after complete surgical excision of deep endometriotic lesions. *Fertil Steril*, 2010, 93, s. 2115–2120.
- Butticé, S. – Laganà, A. S. – Mucciardi, G., et al.: Different patterns of pelvic ureteral endometriosis. What is the best treatment? Results of a retrospective analysis. *Arch Ital Urol Androl*, 2016, 88, s. 266–269.
- Keckstein, J. – Becker, C. M., et al.: Working group of ESGE, ESHRE, and WES: Recommendations for the surgical treatment of endometriosis. Part 2: deep endometriosis. *Hum Reprod Open*, 2020, 1, hoaa002.
- Ceccaroni, M. – Clarizia, R. – Roviglione, G., et al.: Neuroanatomy of the posterior parametrium and surgical considerations for a nervesparing approach in radical pelvic surgery. *Surg Endosc*, 2013, 27, s. 4386–4394.
- Donnez, O. – Roman, H.: Choosing the right surgical technique for deep endometriosis: shaving, disc excision, or bowel resection? *Fertil Steril*, 2017, 108, s. 931–942.
- Abrao, M. S. – Borrelli, G. M. – Clarizia, R., et al.: Strategies for management of colorectal endometriosis. *Semin Reprod Med*, 2017, 35, s. 65–71.
- Ruffo, G. – Scopelliti, F. – Scioscia, M., et al.: Laparoscopic colorectal resection for deep infiltrating endometriosis: analysis of 436 cases. *Surg Endosc*, 2010, 24, s. 63–67.
- Abrao, M. S. – Borrelli, G. M. – Clarizia, R., et al.: Strategies for management of colorectal endometriosis. *Semin Reprod Med*, 2017, 35, s. 65–71.

## Choroby štítné žlázy v graviditě

MUDr. Kristýna Žabková | MUDr. Jan Krátký, Ph.D. | doc. MUDr. Jan Jiskra, Ph.D. III. interní klinika VFN a 1. LF UK, Praha

- Dunn, J. T.: Endemic goiter and cretinism: an update on iodine status. *J Pediatr Endocrinol Metab*, 2001, 14, suppl. 6, s. 1469–1473.
- Glianoer, D. – Fernandez-Soto, M. L. – Bourdoux, P., et al.: Pregnancy in patients with mild thyroid abnormalities: Maternal and neonatal repercussions. *J Clin Endocrinol Metab*, 1991, 71, s. 421–427.
- Pop, V. J. – de Vries, E. – van Baar, A. L., et al.: Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? *J Clin Endocrinol Metab*, 1995, 80, s. 3561–3566.
- Haddow, J. E. – Palomaki, G. E. – Allan, W. C., et al.: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med*, 1999, 341, s. 549–555.
- Thangaratnam, S. – Tan, A. – Knox, E., et al.: Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. *BMJ*, 2011, 342, s. d2616.
- Ghassabian, A. – Bongers-Schokking, J. J. – de Rijke, Y. B., et al.: Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: the Generation R Study. *Thyroid*, 2012, 22, s. 178–186.
- Jiskra, J. – Límanová, Z.: *Doporučení pro prevenci, časný záchyt a léčbu tyreopatií v těhotenství*. 2018, Česká endokrinologická společnost ČLS JEP.
- Horacek, J. – Spitalnikova, S. – Dlabalova, B., et al.: Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. *Eur J Endocrinol*, 2010, 163, s. 645–650.
- Morreale De Escobar, G. – Obregon, M. – Escobar Del Rey, F.: Role of thyroid hormone during early brain development. *Eur J Endocrinol*, 2004, 151, s. U25–U37.
- Korevaar, T. I. – Muetzel, R. – Medici, M., et al.: Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. *Lancet Diabetes Endocrinol*, 2016, 4, s. 35–43.
- Wang, S. – Li, M. – Chu, D., et al.: Clinical or subclinical hypothyroidism and thyroid autoantibody before 20 weeks pregnancy and risk of preterm birth: a systematic review. *Zhonghua Fu Chan Ke Za Zhi*, 2014, 49, s. 816–822.
- Límanová, Z. – Springer, D.: Současné zkušenosti s vyšetřováním tyreopatií v graviditě – výsledky pilotního projektu. *Cas Lek Cesk*, 2011, 150, s. 389–393.
- Límanová, Z.: Specifika léčby tyreopatií v graviditě. *Remedia*, 2014, 24, s. 253–259.
- Límanová, Z.: Štítná žláza a gravidita – souhrn důležitých poznatků. *Vnitř Lék*, 2015, 61, s. 862–867.
- Moreno-Reyes, R. – Glioner, D., et al.: High prevalence of thyroid disorders in pregnant women in a mildly iodine-deficient country: a population-based study. *J Clin Endocrinol Metab*, 2013, 98, s. 3694–3701.
- Zimmermann, M. B.: Methods to assess iron and iodine status. *Br J Nutr*, 2008, 99, suppl. 3, s. S2–9.
- World Health Organization. Urinary iodine concentrations for determining iodine status in populations. World Health Organizations, 2013, dostupné z: <https://apps.who.int/iris/handle/10665/85972>, vyhledáno 11. 5. 2021.
- Davison, J. M. – Dunlop, W.: Renal hemodynamics and tubular function normal human pregnancy. *Kidney Int*, 1980, 18, s. 152–161.
- Bílek, R. – Kaňová, N. – Mindžáková, V., et al.: Zásobení jodem u těhotných žen v České republice. *Vnitř Lék*, 2016, 62, suppl. 3, s. 10–16.

- 20 Alexander, E. K. – Pearce, E. N. – Brent, G. A., et al.: Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid*, 2017, 27, s. 315–389.
- 21 Springer, D. – Zima, T.: Štitná žláza v těhotenství. *News Lab*, 2018, 9, s. 113–119.
- 22 Jiskra, J.: Choroby štítné žlázy v graviditě. *Med Praxi*, 2012, 9, s. 233–237.
- 23 Abalovich, M. – Nobuyuki, A. – Barbour, L. A., et al.: Clinical Practice Guideline. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*, 2007, 92, suppl. 8, s. S1–S47.
- 24 Glihoer, D.: The systematic screening and management of hypothyroidism and hyperthyroidism during pregnancy. *Trends in Endocrinology*, 1998, 9, s. 403–411.
- 25 Burggraaf, J. – Lalezari, S. – Emeis, J. J., et al.: Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. *Thyroid*, 2001, 11, s. 153–160.
- 26 Aggarwal, N. – Suri, V. – Singla, R., et al.: Pregnancy outcome in hyperthyroidism: a case control study. *Gynecol Obstet Invest*, 2014, 77, s. 94–99.
- 27 De Groot, L. – Abalovich, M. – Alexander, E. K., et al.: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, 2012, 97, s. 2543–2565.
- 28 Kahaly, G. J. – Bartalena, L. – Hegedüs, L., et al.: European Thyroid Association guideline for the management of graves' hyperthyroidism. *Eur Thyroid J*, 2018, 7, s. 167–186.
- 29 Negro, R. – Formoso, G. – Mangieri, T., et al.: Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. *J Clin Endocrinol Metab*, 2006, 91, s. 2587–2591.
- 30 Negro, R. – Mangieri, T. – Coppola, L., et al.: Levothyroxine treatment in thyroid peroxidase antibody-positive women undergoing assisted reproduction technologies: a prospective study. *Hum Reprod*, 2005, 20, s. 1529–1533.
- 31 Lazarus, J. – Brown, R. S. – Daumerie, C., et al.: European Thyroid Association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. *Eur Thyroid J*, 2014, 3, s. 76–94.
- 32 Potluková, E. – Jiskra, J. – Telička, Z., et al.: Pozitivita protilátek proti tyreoidální peroxidáze u eutyroidních těhotných žen jako rizikový faktor pozdějšího rozvoje dystyreózy. *Diabetologie – Metabolismus – Endokrinologie – Výživa*, 2011, 14, s. 27–32.
- 33 Potluková, E. – Jiskra, J. – Springer, D., et al.: Vývoj funkce štítné žlázy po porodu u žen zachycených v prvotrimestrálním screeningu tyreopatií. *Diabetologie – Metabolismus – Endokrinologie – Výživa*, 2011, 14, s. 57–58.
- 34 Lemieux, P. – Yamamoto, J. M. – Nerenberg, K. A., et al.: Thyroid laboratory testing and management in women on thyroid replacement before pregnancy and associated pregnancy outcomes. *Thyroid*, 2020, 31, 5, dostupné z: <https://doi.org/10.1089/thy.2020.0609>, vyhledáno 11. 5. 2021.
- 35 Smith, L. H. – Danielsen, B. – Allen, M. E., et al.: Cancer associated with obstetric delivery: results of linkage with the California cancer registry. *Am J Obstet Gynecol*, 2003, 189, s. 1128–1135.
- 36 Vila, L. – Velasco, L. – González, S., et al.: Controversies in endocrinology: On the need for universal thyroid screening in pregnant women. *Eur J Endocrinol*, 2013, 170, s. R17–R30.
- 37 Taylor, P. N. – Okosieme, O. E. – Premawardhana, L., et al.: Should all women be screened for thyroid dysfunction in pregnancy? *Womens Health*, 2015, 11, s. 295–307.
- 38 Thung, S. F. – Funai, E. F. – Grobman, W. A.: The cost effectiveness of universal screening in pregnancy for subclinical hypothyroidism. *Am J Obstet Gynecol*, 2009, 200, s. 267.e1–267.e7.
- 39 Springer, D. – Jiskra, J. – Limanova, Z., et al.: Thyroid in pregnancy: From physiology to screening. *Critical Reviews in Clinical Laboratory Sciences*, 2017, 54, s. 102–116.
- 40 Vaidya, B. – Anthony, S. – Bilous, M., et al.: Detection of thyroid dysfunction in early pregnancy: Universal or targeted high risk case finding? *J Clin Endocr Metab*, 2007, 92v203–207.
- 41 Jiskra, J.: Farmakoterapie nemocí štítné žlázy v graviditě, po porodu a u infertilních žen. In: Fait, T. – Zikán, M. – Mašata, J.: *Moderní farmakoterapie v gynekologii a porodnictví*. Maxdorf, Praha, 2017.
- 42 Ghassabian, A. – Bongers-Schokking, J. J. – de Rijke, Y. B., et al.: Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: the Generation R Study. *Thyroid*, 2012, 22, s. 178–186.

## Diagnostika a prevence preeklampsie

MUDr. Anna Jouzová | MUDr. Lukáš Hruban, Ph.D. Gynekologicko-porodnická klinika LF MU a FN Brno

- 1 Magee, L. A. – Pels, A. – Helewa, M., et al.: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*, 2014, 4, s. 105–145.
- 2 Bell, M. J.: A historical overview of preeclampsia-eclampsia. *J Obstet Gyn Neonat Nurs*, 2010, 39, s. 510–518.
- 3 The American College of Obstetricians and Gynecologists: *Task Force on hypertension in pregnancy*. Washington, 2013, s. 1–99.
- 4 Obeid, N. – O'Kelly, R. – Saadeh, F. A., et al.: A comparison of spot urine protein-creatinine ratio with 24 hour urine protein excretion for prediction of proteinuria in preeclampsia. *Research and Reports in Gynecology and Obstetrics*, 2018, 2, s. 11–15.
- 5 Ahokas, R. – McKinney, E.: Development and physiology of the placenta and membranes. *Glob Libr Women Med*, 2008, DOI 10.3843/GLOWM.10101.
- 6 National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. 2019. Dostupné z: [www.nice.org.uk/guidance/ng133](http://www.nice.org.uk/guidance/ng133), vyhledáno 18. 2. 2021.
- 7 The Fetal Medicine Foundation: Preeclampsia screening, internet-based course. Dostupné z: <https://courses.fetalmedicine.com/fmf/show/813?locale=en>, vyhledáno 18. 2. 2021.
- 8 Gomathy, E. – Akurati, L. – Radhika, K.: Early onset and late onset preeclampsia-maternal and perinatal outcomes in a rural tertiary health center. *Int J Reprod Cont Obstet Gyn*, 2018, 7, 2266, DOI: <http://dx.doi.org/10.18203/2320-1770.ijrcog20182333>.
- 9 Bisták, P.: Screening preeklampsie – pravda, nebo fikce? *Actual Gyn*, 2017, 9, s. 5–9.
- 10 Myers, J. E.: What are the metabolic precursors which increase the risk of pre-eclampsia and how could these be investigated further. *Placenta*, 2017, 60, s. 110–114.
- 11 Papanna, R. – Mann, L. K. – Kouides, R. W., et al.: Protein/creatinine ratio in preeclampsia: a systematic review. *Obst Gyn*, 2008, 112, s. 135–144.
- 12 Hladunewich, M. – Karumanchi, S. A. – Lafayette, R.: Pathophysiology of the clinical manifestations of preeclampsia. *CJASN*, 2007, 2, s. 543–549.
- 13 Magee, L. A. – von Dadelszen, P. – Stones, W., et al.: *The FIGO Text book of Pregnancy Hypertension: an evidence-based guide to monitoring, prevention and management*. Londýn, 2016.
- 14 Boyd, C. – Wood, K. – Whitaker, D., et al.: Accuracy in 24-hour urine collection at a tertiary center. *Rev Urology*, 2018, 20, s. 119–124.
- 15 Côté, A.-M. – Firoz, T. – Mattman, A., et al.: The 24-hour urine collection: gold standard or historical practice? *Am J Obstet Gyn*, 2008, 199, 625, s. e1–e6.
- 16 Miler, M. – Šimundić, A.-M.: Low level of adherence to instructions for 24-hour urine collection among hospital outpatients. *Biochimica Medica*, 2013, s. 316–320.
- 17 Rodby, R. A.: Timed Urine Collections for Albumin and Protein: The King Is Dead, Long Live the King! *Am J Kidney Diseases*, 2016, 68, s. 836–838.
- 18 Schück, O.: Perspektivy: Je nutný 24hodinový sběr moči pro přesné stanovení proteinurie a glomerulární filtrace? *Postgraduální neurologie*, 2006, 6, s. 34.
- 19 Kyle, P. – Fielder, J. – Pullar, B., et al.: Comparison of methods to identify significant proteinuria in pregnancy in the outpatient setting. *Int J Obstet Gyn*, 2008, 115, s. 523–527.
- 20 Lamb, E. J. – MacKenzie, F. – Stevens, P. E.: How should proteinuria be detected and measured? *An Clin Biochemistry*, 2009, 46, s. 205–217.
- 21 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. *Kidney International Supplements*, 2012, 2, s. 139–274.
- 22 Zima, T. – Racek, J. – Tesaf, V., et al.: Doporučení k diagnostice chronického onemocnění ledvin (odhad glomerulární filtrace a vyšetřování proteinurie). *Klin Biochem Metab*, 2014, 22, s. 138–152.
- 23 Lowe, S. A. – Bowyer, L. – Lust, K., et al.: The SOMANZ guidelines for the management of hypertensive disorders of pregnancy, 2014. *Austr New Zealand J Obstet Gyn*, 2015, 55, s. e1–e29.
- 24 Duley, L.: The global impact of pre-eclampsia and eclampsia. *Semin Perinatol*, 2009, 33, s. 130–137.
- 25 Poon, L. C. – Sahota, D.: Screening and prevention of preeclampsia. *Maternal-Fetal Med*, 2019, 1, s. 25–30.
- 26 O'Gorman, N. – Wright, D. – Poon, L. C., et al.: Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation. *Ultrasound Obstet Gyn*, 2017, 49, s. 751–755.
- 27 Chaemsaitong, P. – Sahota, D. S. – Poon, L. C.: First trimester preeclampsia screening and prediction. *Am J Obstet Gyn*, 2020, doi: [10.1016/j.ajog.2020.07.020](https://doi.org/10.1016/j.ajog.2020.07.020).
- 28 Rolnik, D. L. – Wright, D. – Poon, L. C., et al.: Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. *New Eng J Med*, 2017, 377, s. 613–622.
- 29 Rolnik, D. L. – Wright, D. – Poon, L. C. Y., et al.: ASPRE trial: performance of screening for preterm pre-eclampsia. *Ultrasound Obstet Gynecol*, 2017, 50, s. 492–495.

## SiderAL Folic – lékový profil

MUDr. Peter Koliba Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- 1 Kassebaum, N. J. – Jasarasaria, R. – Naghavi, M., et al.: A systematic analysis of global anemia burden from 1990 to 2010. *Blood*, 2014, 123, s. 615–624.
- 2 Muñoz, M. – García-Erce, J. A. – Remacha, A. F.: Disorders of iron metabolism. Part II: Iron deficiency and iron overload. *J Clin Pathol*, 2011, 64, s. 287–296.
- 3 Milman, N.: Prepartum anemia: prevention and treatment. *Ann Hematol*, 2008, 87, s. 949–959.
- 4 Lain, K. Y. – Catalano, P. M.: Metabolic changes in pregnancy. *Clin Obstet Gynecol*, 2007, 50, s. 938–948.
- 5 Blumfield, M. L. – Hure, A. J. – Macdonald-Wicks, L., et al.: A systematic review and meta-analysis of micronutrient intakes during pregnancy in developed countries. *Nutr Rev*, 2013, 71, s. 118–132.
- 6 Wilhelm, Z.: Co je dobré vědět o železe. *Prakt Lékáren*, 2007, 3, s. 41–44.
- 7 Fabiano, A. – Brilli, E. – Fogli, S., et al.: Sucrosomial iron absorption studied by in vitro and ex-vivo models. *Eur J Pharm Sci*, 2018, 111, s. 425–431.
- 8 Brilli, E. – Lipinski, P. – Barnadas-Rodriguez, R., et al.: Sucrosomial iron absorption involve M cells. *Blood*, 2017, 130, s. 2217.
- 9 Gómez-Ramírez, S. – Brilli, E. – Tarantino, G., et al.: Sucrosomial iron: a new generation iron for improving oral supplementation. *Pharmaceuticals*, 2018, 11, s. 97.
- 10 Tarantino, G. – Brilli, E. – Zambito, Y., et al.: Sucrosomial iron: A new highly bioavailable oral iron supplement. *Blood*, 2015, 126, s. 4561–4562.
- 11 Starzynski, R. – Szudzik, M. – Staron, R., et al.: Comparison of the therapeutic potential of oral Sucrosomial iron and parenteral iron dextran supplementations in neonatal iron deficiency anemia in pigs. *Am J Hematol*, 2017, 92, s. E286.
- 12 Asperti, A. – Gryzik, M. – Brilli, E., et al.: Sucrosomial iron supplementation in mice: Effects on blood parameters, hepcidin, and inflammation. *Nutrients*, 2018, 10, s. 1349.
- 13 Elli, L. – Ferretti, F. – Branchi, F., et al.: Sucrosomial iron supplementation in anemic patients with celiac disease not tolerating oral ferrous sulfate: A prospective study. *Nutrients*, 2018, 10, s. 330.
- 14 Ciudin, A. – Simo-Servat, O. – Balibrea, J. M., et al.: Response to oral Sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. *Endocrinol Diabetes Nutr*, 2018, 65, s. 17–20.
- 15 Mafodda, A. – Giuffrida, D. – Prestifilippo, A., et al.: Oral Sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: A pilot study. *Support Care Cancer*, 2017, 25, s. 2779–2786.
- 16 Pisani, A. – Riccio, E. – Sabbatini, M., et al.: Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anemia in CKD patients: A randomized trial. *Nephrol Dial Transplant*, 2015, 30, s. 645–652.
- 17 Capra, A. P. – Ferro, E. – Cannavò, L., et al.: A child with severe iron-deficiency anemia and a complex Tmprss6 genotype. *Hematology*, 2017, 22, s. 559–564.
- 18 Muñoz, M. – Peña-Rosas, J. P. – Robinson, S., et al.: Patient blood management in obstetrics: Management of anemia and haematitic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. *Transfus Med*, 2018, 28, s. 22–39.
- 19 Fonseca, C. – Araujo, M. – Moniz, P., et al.: Prevalence and prognostic impact of anemia and iron deficiency in patients hospitalized in an internal medicine ward: The PRO-IRON study. *Eur J Haematol*, 2017, 99, s. 505–513.
- 20 Parisi, F. – Berti, C. – Mando, C., et al.: Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: A randomized control trial. *J Matern Fetal Neonatal Med*, 2017, 30, s. 1787–1792.
- 21 Berardi, S. – Foltran, L. – Pascoli, L., et al.: Efficacy of oral Sucrosomial iron in puerperium anemia. *Exp Rev Hematol*, 2016, 9, suppl. S1, s. 40.

# Angusta – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- Vogel, J. P. – Osoti, A. O. – Kelly, A. J., et al.: Pharmacological and mechanical interventions for labour induction in outpatient settings. *Cochrane Database Syst Rev*, 2017, 9, CD007701.
- ten Eikelder, M. L. – Oude Rengerink, R. K. – Jozwiak, M., et al.: Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial. *Lancet*, 2016, 387, s. 1619–1628.
- ACOG Practice Bulletin No. 107: Induction of labor. *Obstet Gynecol*, 2009, 114, s. 386–397.
- Jozwiak, M. – Oude, R. K. – Benthem, M., et al.: Foley catheter versus vaginal prostaglandin E2 gel for induction of labour at term (PROBAAT trial): an open-label, randomised controlled trial. *Lancet*, 2011, 378, s. 2095–2103.
- Alfirevic, Z. – Aflaifel, N. – Weeks, A.: Oral misoprostol for induction of labour. *Cochrane Database Syst Rev*, 2014, CD001338.
- Elati, A. – Weeks, A. D.: The use of misoprostol in obstetrics and gynaecology. *Br J Obstet Gynaecol*, 2009, 116, suppl. 1, s. 61–69.
- Bakker, R. – Pierce, S. – Myers, D.: The role of prostaglandins E1 and E2, dinoprostone, and misoprostol in cervical ripening and the induction of labor: a mechanistic approach. *Arch Gynecol Obstet*, 2017, 296, s. 167–179.
- Tang, O. S. – Gemzell-Danielsson, K. – Ho, P. C.: Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. *Int J Gynaecol Obstet*, 2007, 99, suppl. 2, s. S160–S167.
- Hofmeyr, G. J. – Gulmezoglu, A. M. – Alfirevic, Z.: Misoprostol for induction of labour: a systematic review. *Br J Obstet Gynaecol*, 1999, 106, s. 798–803.
- Stephenson, M. L. – Wing, D. A.: Misoprostol for induction of labor. *Semin Perinatol*, 2015, 39, s. 459–462.
- Hofmeyr, G. J. – Alfirevic, Z. – Matonhodze, B., et al.: Titrated oral misoprostol solution for induction of labour: a multi-centre, randomised trial. *Br J Obstet Gynaecol*, 2001, 108, s. 952–959.
- Dodd, J. M. – Crowther, C. A. – Robinson, J. S.: Oral misoprostol for induction of labour at term: randomised controlled trial. *BMJ*, 2006, 332, s. 509–513.
- Bendix, J. M. – Friis, P. J. – Andersen, B. R., et al.: Induction of labor with high- or low-dosage oral misoprostol-A. Danish descriptive retrospective cohort study 2015-16. *Acta Obstet Gynecol Scand*, 2020, 99, s. 222–230.
- Helmig, R. B. – Hvidman, L. E.: An audit of oral administration of Angusta(R) (misoprostol) 25 microg for induction of labor in 976 consecutive women with a singleton pregnancy in a university hospital in Denmark. *Acta Obstet Gynecol Scand*, 2020, 99, s. 1396–1402.

# Perorální misoprostol k indukci porodu. Komentář k článku Angusta – lékový profil

MUDr. Jan Matěcha Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- Grobman, W. A., et al.: Labor induction versus expectant management in low-risk nulliparous women. *N Engl J Med*, 2018, 379, s. 513–523.
- Alfirevic, Z. – Aflaifel, N. – Weeks, A.: Oral misoprostol for induction of labour. *Cochrane Database Syst Rev*, 2014, 2014, s. Cd001338.
- Alfirevic, Z., et al.: Labour induction with prostaglandins: a systematic review and network meta-analysis. *BMJ*, 2015, 350, s. h217.
- WHO Guidelines Approved by the Guidelines Review Committee, in WHO Recommendations for Induction of Labour. 2011, World Health Organization
- Morris, J. L., et al.: FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. *Int J Gynaecol Obstet*, 2017, 138, s. 363–366.
- Plaut, M. M. – Schwartz, M. L. – Lubarsky, S. L.: Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. *Am J Obstet Gynecol*, 1999, 180, s. 1535–1542.
- Makarem, M. H., et al.: Early amniotomy after vaginal misoprostol for induction of labor: a randomized clinical trial. *Arch Gynecol Obstet*, 2013, 288, s. 261–265.
- Helmig, R. B. – Hvidman, L. E.: An audit of oral administration of Angusta (misoprostol) 25 µg for induction of labor in 976 consecutive women with a singleton pregnancy in a university hospital in Denmark. *Acta Obstet Gynecol Scand*, 2020, 99, s. 1396–1402.
- Bishop, E. H.: Pelvic scoring for elective induction. *Obstet Gynecol*, 1964, 24, s. 266–268.

# Léčba mykotických infekcí v gynekologii

doc. MUDr. Petr Hamal, Ph.D. | MDDr. Lucie Svobodová Ústav mikrobiologie LF UP a Fakultní nemocnice Olomouc

- Achkar, J. M. – Fries, B. C.: Candida infections of the genitourinary tract. *Clin Microbiol Rev*, 2010, 23, s. 253–273.
- Spence, D.: Candidiasis (vulvovaginal). *BMJ Clin Evid*, 2010, 0815.
- Odds, F. – Webster, C. E. – Mayuranathan, P., et al.: Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. *J Med Vet Mycol*, 1988, 26, s. 277–283.
- Beigi, R. H. – Meyn, L. A. – Moore, D. M., et al.: Vaginal yeast colonization in nonpregnant women: a longitudinal study. *Obstet Gynecol*, 2004, 104, s. 926–930.
- Landers, D. V. – Wiesenfeld, H. C. – Heine, R. P., et al.: Predictive value of the clinical diagnosis of lower genital tract infection in women. *Am J Obstet Gynecol*, 2004, 190, s. 1004–1010.
- Cauwenbergh, G.: Vaginal candidiasis: Evolving trends in the incidence and treatment of non-Candida albicans infection. *Curr Probl Obstet Gynecol Fertil*, 1990, 8, s. 241–245.
- Lian, C. – Zhao, J. – Zhang, Z., et al.: Genotype of Candida species associated with different conditions of vulvovaginal candidosis. *Mycoses*, 2004, 47, s. 495–502.
- Slutsky, B. – Buffo, J. – Soll, D. R.: High-frequency switching of colony morphology in Candida albicans. *Science*, 1985, 230, s. 666–669.
- Chong, P. P. – Lee, Y. L. – Tan, B. C., et al.: Genetic relatedness of Candida strains isolated from women with vaginal candidiasis in Malaysia. *J Med Microbiol*, 2003, 52, s. 657–666.
- Hamal, P.: Vulvovaginální kandidózy. *I-med*, 2013, 3; dostupné z: <http://www.i-med.sk/moodle/form/pdf.php?id=1276&action=text>, vyhledáno 11. 5. 2021.
- Svobodová, L. – Lysková, P. – Hamal, P.: Kandidová vulvovaginitida. *Klin Mikrobiol Inf Lek*, 2015, 21, s. 74–81.
- Reef, S. E. – Levine, W. C. – McNeil, M. M., et al.: Treatment options for vulvovaginal candidiasis, 1993. *Clin Infect Dis*, 1995, 20, suppl. 1, s. S80–S890.
- Watson, M. C. – Grimshaw, J. M. – Bond, C. M., et al.: Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. *BJOG*, 2002, 109, s. 85–95.
- Ferris, D. G. – Nyirjesy, P. – Sobel, J. D., et al.: Over-the-counter anti-fungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. *Obstet Gynecol*, 2002, 99, s. 419–425.
- Mending, W. – Brasch, J.: Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infect Immunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. *Mycoses*, 2012, 55, suppl. 3, s. 1–13.
- Dovnik, A. – Golle, A. – Novak, D., et al.: Treatment of vulvovaginal candidiasis: a review of the literature. *Acta Dermatovenerol Alp Pannonica Adriat*, 2015, 24, s. 5–7.
- Pappas, P. G. – Kauffman, C. A. – Andes, D., et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 2009, 48, s. 503–535.
- Sekhavat, L. – Tabatabaai, A. – Tezerjani, F. Z.: Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. *J Infect Public Health*, 2011, 4, s. 195–199.
- Workowski, K. A. – Berman, S. M.: Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recommend Rep*, 2006, 55, s. 1–94.
- Mending, W. – Schlegelmilch, R.: Three-day combination treatment for vulvovaginal candidosis with 200 mg clotrimazol vaginal suppositories and clotrimazol cream for the vulva is significantly better than treatment with vaginal suppositories alone – an earlier, multi-centre, placebo-controlled double blind study. *Geburtschilfe Frauenheilkunde*, 2014, 74, s. 355–360.
- Pirotta, M. V. – Garland, S. M.: Her choice: dealing with lactobacilli, vaginitis, and antibiotics. *Curr Infect Dis Rep*, 2005, 7, s. 445–452.
- Peters, B. M. – Yano, J. – Noverr, M. C., et al.: Candida vaginitis: when opportunism knocks, the host responds. *PLoS Pathog*, 2014, 10, e1003965.
- Sobel, J. D.: Vulvovaginal candidosis. *Lancet*, 2007, 369, s. 1961–1971.
- Horák, P.: Vulvovaginální kandidóza farmakoterapie a prevence. *Praktické lékařství*, 2011, 7, s. 80–84.
- Donders, G. – Bellen, G. – Byttebier, G., et al.: Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). *Am J Obstet Gynecol*, 2008, 199, s. 613 e1–e9.
- Sobel, J. D. – Wiesenfeld, H. C. – Martens, M., et al.: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med*, 2004, 351, s. 876–883.
- Gomez-Moyano, E. – Cid Lama, A. – Fernández Ballesteros, M. D., et al.: Efficacy of voriconazole treatment in chronic vulvovaginal candidosis due to Candida glabrata. *Micologia*, 2013, s. 61–63. Dostupné z: <http://www.reviberommicol.com/2013-30/index.shtml>, vyhledáno 11. 5. 2021.
- Špaček, J. – Buchta, V. – Jilek, P., et al.: Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. *Eur J Obstet Gynecol Reprod Biol*, 2007, 131, s. 198–202.
- Bauters, T. G. – Dhont, M. A. – Temmerman, M. I., et al.: Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. *Am J Obstet Gynecol*, 2002, 187, s. 569–574.
- Guaschino, S. – De Seta, F. – Sartore, A., et al.: Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. *Am J Obstet Gynecol*, 2001, 184, s. 598–602.

# Teriparatid v léčbě osteoporózy i ostatních skeletálních onemocnění a komplikací

doc. MUDr. Václav Vyskočil, Ph.D. II. interní klinika – Osteocentrum, Klinika ortopedie a traumatologie pohybového ústrojí – Trauma centrum, FN Plzeň a LF UK, Plzeň

- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA*, 2001, 285, s. 785–795.
- Nevitt, M. C. – Ettinger, B. – Black, D. M., et al.: The association of radiographically detected vertebral fractures with backpain and function: a prospective study. *Ann Intern Med*, 1998, 128, s. 793–800.

- 3 Melton, L. J. 3rd, Lane, A. W., Cooper, C., et al.: Prevalence and incidence of vertebral deformities. *Osteoporos Int*, 1993, 3, s. 113–119.
- 4 Kanis, J. A., Geusens, P., Christiansen, C.: Guidelines for clinical trials in osteoporosis. A position paper of the European Foundation for Osteoporosis and Bone Disease. *Osteoporos Int*, 1991, 1, s. 182–188.
- 5 Greendale, G. A., Silverman, S. L., Hays, R. D., et al.: Health-related quality of life in osteoporosis clinical trials. The Osteoporosis Quality of Life Study Group. *Calcif Tissue Int*, 1993, 53, s. 75–77.
- 6 Ross, P. D., Ettinger, B., Davis, J. W., et al.: Evaluation of adverse health outcomes associated with vertebral fractures. *Osteoporos Int*, 1991, 1, s. 134–140.
- 7 Oleksik, A., Lips, P., Dawson, A., et al.: Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. *J Bone Miner Res*, 2000, 15, s. 1384–1392.
- 8 Barker, K. L., Javaid, M. K., Newman, M., et al.: Physiotherapy Rehabilitation for Osteoporotic Vertebral Fracture (PROVE): study protocol for a randomised controlled trial. *Trials*, 2014, 15, s. 22.
- 9 Bilotta, C., Bowling, A., Nicolini, P., et al.: Older People's Quality of Life (OPQOL) scores and adverse health outcomes at a one-year follow-up. A prospective cohort study on older outpatients living in the community in Italy. *Health Qual Life Outcomes*, 2011, 9, s. 72.
- 10 Silverberg, S. J., Shane, E., de la Cruz, L., et al.: Skeletal disease in primary hyperparathyroidism. *J Bone and Miner Res*, 1989, 4, s. 283–291.
- 11 Dempster, D. W., Müller, R., Zhou, H., et al.: Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. *Bone*, 2007, 41, s. 19–24.
- 12 Terauchi, M., Li, J. Y., Bedi, B., et al.: T lymphocyte simplify the anabolic activity of parathyroid hormone through Wnt10b signaling. *Cell Metab*, 2009 Sep;10(3):229–240.
- 13 Bellido, T., Ali, A. A., Gubrij, I., et al.: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. *Endocrinology*, 2005, 146, s. 4577–4583.
- 14 Girotra, M., Cosman, F., Bilezikian, J. P.: Treatment of male osteoporosis with parathyroid hormone. In: Orwoll, E. S., Bilezikian, J. P., Vanderschueren, D. (eds.): *Osteoporosis in Men*. Burlington, Mass, USA Academic Press, 2010, s. 681–690.
- 15 Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., et al.: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med*, 2001, 344, s. 1434–1441.
- 16 Krege, J. H., Wan, X., et al.: Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. *Bone*, 2012, 50, s. 161–164.
- 17 Dobnig, H., Sipos, A., Jiang, Y., et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. *J Clin Endocrinol Metab*, 2005, 90, s. 3970–3977.
- 18 Nishiyama, K. K., Cohen, A., Young, P., et al.: Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. *J Clin Endocrinol Metab*, 2014, 99, s. 2418–2425.
- 19 Cosman, F., Keaveny, T. M., Kopperdahl, D., et al.: Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. *J Bone Miner Res*, 2013, 28, s. 1328–1336.
- 20 Graeff, C., Chevalier, Y., Charlebois, M., et al.: Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFOR study. *J Bone Miner Res*, 2009, 24, s. 1672–1680.
- 21 Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., et al.: Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. *J Bone Miner Res*, 2008, 23, s. 1591–1600.
- 22 Niimi, T., Kono, A., Nishihara, M., et al.: An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. *Osteoporos Int*, 2014, 25, s. 377–384.
- 23 Krege, J. H., Lane, N. E., Harris, J. M., et al.: PINP as a biological response marker during teriparatide treatment for osteoporosis. *Osteoporos Int*, 2014, 25, s. 2159–2171.
- 24 Stepan, J. J., Burr, D. B., Li, J., et al.: Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. *Osteoporos Int*, 2010, 21, s. 2027–2036.
- 25 Farahmand, P., Marin, F., Hawkins, F., et al.: Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. *Osteoporos Int*, 2013, 24, s. 2971–2981.
- 26 Chevalier, Y., Quek, E., Borah, B., et al.: Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risendronate: results from quantitative computed tomography based finite element analysis of the vertebral body. *Bone*, 2010, 46, s. 41–48.
- 27 Recker, R. R., Marin, F., Ish-Shalom, S., et al.: Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. *J Bone Miner Res*, 2009, 24, s. 1358–1368.
- 28 Blumsohn, A., Marin, A., Nickelsen, T., et al.: Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. *Osteoporos Int*, 2011, 22, s. 1935–1946.
- 29 Tsujimoto, P., Chen, A., Miyauchi, H., et al.: PINP as an aid for monitoring patients treated with teriparatide. *Bone*, 2011, 48, s. 798–803.
- 30 SPC FORSTEO, dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0025491&tab=texts>, vyhledáno 13. 5. 2021.
- 31 Geusens, P., Marin, F., Kendler, D. L., et al.: Effects of teriparatide compared with risendronate on the risk of fractures in sub groups of postmenopausal women with severe osteoporosis: The VERO Trial. *J Bone Miner Res*, 2018, 33, s. 783–794.
- 32 DelPuente, A., Scognamiglio, A., Iltto, E., et al.: Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. *J Rheumatol*, 2000, 27, s. 1980–1983.
- 33 Heckman, G. A., Papaioannou, A., Sebold, R. J., et al.: Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. *BMC Musculoskeletal Disord*, 2002, 3, s. 1–6.
- 34 Sawka, A. M., Adachi, J. D., Ioannidis, G., et al.: What predicts early fracture or bone loss on bisphosphonate therapy. *J Clin Densitom*, 2003, 6, s. 315–322.
- 35 Lewiecki, E. M.: Nonresponders to osteoporosis therapy. *J Clin Densitom*, 2003, 6, s. 307–314.
- 36 National Institute for Clinical Excellence. Final appraisal determination – secondary prevention of osteoporotic fragility fractures in postmenopausal women. 2004, s. 1–48.
- 37 Jakob, F., Marin, F., Martin-Mola, E., et al.: Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). *QJM*, 2006, 99, s. 531–543.
- 38 Adami, S., Isaia, G., Luisetto, G., et al.: Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. *J Bone Miner Res*, 2006, 21, s. 1565–1570.
- 39 Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., et al.: Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. *J Bone Miner Res*, 2008, 23, s. 1591–1600.
- 40 Diez-Pérez, A., González-Macias, J.: Inadequate responders to osteoporosis treatment: proposal for an operational definition. *Osteoporos Int*, 2008, 19, s. 1511–1516.
- 41 Diez-Pérez, A., Adachi, J. D., Agnusdei, D., et al.: Treatment failure in osteoporosis. *Osteoporos Int*, 2012, 23, s. 2769–2774.

## Histiocytóza z Langerhansových buněk je imitátorkou četných jiných chorob. Klinické obrazy, diagnostika a přehled léčebných postupů v roce 2021

prof. MUDr. Zdeněk Adam, CSc. Interní hematologická klinika LF MU a FN Brno

MUDr. Marta Ježová, Ph.D. Patologický ústav LF MU a FN Brno

MUDr. Tomáš Nebeský, CSc. Radiologická klinika LF MU a FN Brno

doc. MUDr. Zdeněk Řehák, Ph.D. | MUDr. Renata Koukalová PET CT oddělení, Masarykův onkologický ústav, Brno

MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení Vsetínské nemocnice

prof. MUDr. Luděk Pour, Ph.D. | prof. MUDr. Marta Krejčí, Ph.D. | MUDr. Martin Štork, Ph.D. Interní hematologická klinika

LF MU a FN Brno

- 1 Nicholson, S. H., Egeler, M., Nesbit, M. E.: The epidemiology of Langerhans cell histiocytosis. *Hematol Oncol Clin North Amer*, 1998, 12, s. 379–348.
- 2 Baumgartner, L., Hochstetter, A., Baumert, B., et al.: Langerhans cell histiocytosis in adults. *Med Pediatric Oncol*, 1997, 28, s. 9–14.
- 3 Kobayashi, M., Tojo, A.: Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment. *Cancer Sci*, 2018, 109, s. 3707–3713.
- 4 Bonometti, A., for Associazione Italiana Ricerca Istiocitosis: The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification. *Leuk Lymphoma*, 2021, 62, s. 32–44.
- 5 Badalian-Very, G., et al.: Recurrent BRAF mutations in Langerhans cell histiocytosis. *Blood*, 2010, 116, s. 1919–1923.
- 6 Badalian-Very, G., et al.: Pathogenesis of Langerhans cell histiocytosis. *Annu Rev Pathol*, 2013, 24, s. 1–20.
- 7 Egeler, R. M., et al.: Association of Langerhans cell histiocytosis with malignant neoplasms. *Cancer*, 1993, 71, s. 865–873.
- 8 Lee, J. S., et al.: Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. *J Korean Med Sci*, 2006, 21, s. 577–580.
- 9 Lau, S. K., Chu, P. G., Weiss, L. M.: Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytotic disorders. *Am J Surg Pathol*, 2008, 32, s. 615–619.
- 10 Swerdlow, S. H., Campo, E., Harris, N. L., et al.: International Agency for Research on Cancer. *WHO classification of tumours of haematopoietic and lymphoid tissues*. International Agency for Research on Cancer (IARC), 2008.
- 11 Valladeau, J., et al.: Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. *Immunity*, 2000, 12, s. 71–81.
- 12 Rodriguez-Galindo, C., Allen, C. E.: Langerhans cell histiocytosis. *Blood*, 2020, 135, s. 1319–1331.
- 13 Reisi, N., Raeissi, P., Harati Khalilabad, T., et al.: Unusual sites of bone involvement in Langerhans cell histiocytosis: a systematic review of the literature. *Orphanet Journal of Rare Diseases*, 2021, 16, 1.
- 14 St Claire, K., Bunney, R., Ashack, K. A., et al.: Langerhans cell histiocytosis: A great imitator. *Clin Dermatol*, 2020, 38, s. 223–234.
- 15 Adam, Z., Řehák, Z., Koukalová, R., et al.: Přínos PET-CT pro diagnostiku a sledování plicní formy histiocytózy z Langerhansových buněk. *Vnitřní lék*, 2010, 56, s. 123–130.
- 16 Lorillon, G., Tazi, A.: How I manage pulmonary Langerhans cell histiocytosis. *European Respiratory Review*, 2017, 26, 170070; DOI: 10.1183/16000617.0070-2017.
- 17 Le Guen, P., Chevret, S., Bugnet, E., et al.: Management and outcomes of pneumothorax in adult patients with Langerhans cell histiocytosis. *Orphanet J Rare Dis*, 2019, 14, 229, doi: 10.1186/s13023-019-1203-5.
- 18 Yeh, E. A., Greenberg, J., Ablu, O., et al.: North American Consortium for Histiocytosis: Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. *Pediatr Blood Cancer*, 2018, 65, doi: 10.1002/pbc.26784.
- 19 Wang, Y., Camelo-Piragua, S., Abdullah, A., et al.: Neuroimaging features of CNS histiocytosis syndromes. *Clin Imaging*, 2020, 60, s. 131–140.
- 20 Fassmann, A., Izakovičová-Hollá, L., Augustín, P., et al.: Projevy histiocytózy z Langerhansových buněk v orofaciální oblasti. *Vnitřní Léč*, 2010, 56, s. 85–90.
- 21 Singhi, A. D., Montgomery, E. A.: Gastrointestinal tract Langerhans cell histiocytosis: A clinicopathologic study of 12 patients. *Am J Surg Pathol*, 2011, 35, s. 305–310.
- 22 Goyal, G., Young, J. R., Koster, M. J., et al.: The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytotic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. *Mayo Clin Proc*, 2019, 94, s. 2054–2071.
- 23 Arico, M.: Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. *Eur J Cancer*, 2003, 39, s. 2341–2348.
- 24 Girschikofsky, M., Arico, M., Castillo, D., et al.: Management of adult patients with Langerhans cell histiocytosis, recommendation from an expert panel on behalf of Euro-Histo Net. *Orphanet J Rare Disease*, 2013, 8, s. 72–78.
- 25 Lorillon, G., Tazi, A.: How I manage pulmonary Langerhans cell histiocytosis. *Eur Respir Rev*, 2017, 26, s. pii: 170070.
- 26 Phillips, M., et al.: Comparison of FDG-PET scans to conventional

- radiography and bone scans in management of Langerhans cell histiocytosis. *Pediatr Blood Cancer*, 2009, 52, s. 97–101.
- 27 Szturz, P. – Adam, Z. – Krejčí, M.: Lymfom podobný průběh agresivní multisystémové histiocytózy z Langerhansových buněk a přínos F PET/CT vyšetření a vyhodnocení difúzní plicní metabolické aktivity. *Vnitř Lék*, 2010, 56, s. 1177–1193.
  - 28 Teng, C. L., et al.: Rapidly fatal Langerhans' cell histiocytosis in an adult. *J Formos Med Assoc*, 2005, 104, s. 955–959.
  - 29 Grois, N., et al.: Risk factors for diabetes insipidus in Langerhans cell histiocytosis. *Pediatr Blood Cancer*, 2006, 46, s. 228–233.
  - 30 Makras, P., et al.: Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. *Pediatr Blood Cancer*, 2012, 58, s. 819–822.
  - 31 Yasko, A. W., et al.: Percutaneous techniques for the diagnosis and treatment of localized Langerhans-cell histiocytosis (eosinophilic granuloma of bone). *J Bone Joint Surg Am*, 1998, 80, s. 219–228.
  - 32 Cantu, M. A., et al.: Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. *PLoS One*, 2012, 7, s. e43257.
  - 33 Lo, W. C., et al.: Isolated adult Langerhans' cell histiocytosis in cervical lymph nodes: should it be treated? *J Laryngol Otol*, 2009, 123, s. 1055–1057.
  - 34 Sakai, H., et al.: Satisfactory remission achieved by PUVA therapy in Langerhans cell histiocytosis in an elderly patient. *J Dermatol*, 1996, 23, s. 42–46.
  - 35 Imafuku S., et al.: Cutaneous Langerhans cell histiocytosis in an elderly man successfully treated with narrowband ultraviolet B. *Br J Dermatol*, 2007, 157, s. 1277–1279.
  - 36 Adam, Z. – Ježová, M. – Šlampa, P., et al.: Indeterminate cell histiocytosis – disappearance of skin infiltration following electron beam therapy and an application of 2-chlorodeoxyadenosine: case report. *Vnitř Lék*, 2017, 63, s. 284–288.
  - 37 Sander, C. S. – Kaatz, M. – Elsner, P.: Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide. *Dermatology*, 2004, 208, s. 149–152.
  - 38 McClain, K. L. – Kozinetz, C. A.: A phase II trial using thalidomide for Langerhans cell histiocytosis. *Pediatr Blood Cancer*, 2007, 48, s. 44–49.
  - 39 Steen, A. E., et al.: Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. *Br J Dermatol*, 2001, 145, s. 137–140.
  - 40 Saven, A. – Burian, C.: Cladribine activity in adult Langerhans-cell histiocytosis. *Blood*, 1999, 93, s. 4125–4130.
  - 41 Dimopoulos, M. A. – Theodorakis, M. – Kostis, E., et al.: Treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. *Leuk Lymphoma*, 1997, 25, s. 187–189.
  - 42 Donadieu, J. – Bernard, F. – van Noesel, M., for Salvage Group of the Histiocyte Society: Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. *Blood*, 2015, 126, s. 1415–1423.
  - 43 Nasser, M. – Tracllet, J. – Cottin, V.: Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis. *ERJ Open Res*, 2018, 4, s. 00089–2017.
  - 44 Rosso, D. A. – Amaral, D. A. – Latella, A., et al.: Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis. *Br J Haematol*, 2016, 172, s. 287–290.
  - 45 Grobost, V. – Khouatra, C. – Lazor, R., et al.: Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. *Orphanet J Rare Dis*, 2014, 9, s. 191.
  - 46 Lorillon, G. – Bergeron, A. – Detournignies, L., et al.: Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. *Am J Respir Crit Care Med*, 2012, 186, s. 930–932.
  - 47 Schini, M. – Makras, P. – Kanakis, G., et al.: Cladribine therapy in adults with advanced Langerhans cell histiocytosis. *Leuk Lymphoma*, 2013, 54, s. 1541–1543.
  - 48 Adam, Z. – Szturz, P. – Vaníček, J., et al.: Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases. *Acta Oncol*, 2013, 52, s. 994–1001.
  - 49 Black, A. – Bershaw, A. – Allen, P. S., et al.: Seventy-nine-year-old man with Langerhans cell histiocytosis treated with cladribine. *J Am Acad Dermatol*, 2011, 65, s. 681–683.
  - 50 Baumann, M. – Cerny, T. – Sommacal, A., et al.: Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. *Hematol Oncol*, 2012, 30, s. 101–104.
  - 51 Lazor, R. – Etienne-Mastroianni, B. – Khouatra, C., et al.: Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. *Thorax*, 2009, 64, s. 274–275.
  - 52 Apollonsky, N. – Lipton, J. M.: Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. *J Pediatr Hematol Oncol*, 2009, 31, s. 53–56.
  - 53 Aerni, M. R. – Aubry, M. C. – Myers, J. L., et al.: Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker. *Respir Med*, 2008, 102, s. 316–319.
  - 54 Dhall, G. – Finlay, J. L. – Dunkel, I. J., et al.: Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. *Pediatr Blood Cancer*, 2008, 50, s. 72–79.
  - 55 Mottl, H. – Starý, J. – Chánová, M., et al.: Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. *Leuk Lymphoma*, 2006, 47, s. 1881–1884.
  - 56 McClain, K. L.: Drug therapy for the treatment of Langerhans cell histiocytosis. *Expert Opin Pharmacother*, 2005, 6, s. 2435–2441.
  - 57 Goh, N. S. – McDonald, C. E. – MacGregor, D. P., et al.: Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. *Respirology*, 2003, 8, s. 91–94.
  - 58 Pardanani, A. – Phylliky, R. L. – Li, C. Y., et al.: 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. *Mayo Clin Proc*, 2003, 78, s. 301–306.
  - 59 Rodriguez-Galindo, C. – Kelly, P., et al.: Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. *Am J Hematol*, 2002, 69, s. 179–184.
  - 60 Salama, H. A. – Jazieh, A. R. – Alhejazi, A. Y., et al.: Highlights of the management of adult histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease, and hemophagocytic lymphohistiocytosis. *Clin Lymphoma Myeloma Leuk*, 2020, S2152-2650, s. 30422–30425.
  - 61 Néel, A. – Artifoni, M. – Fontenoy, A. M., et al.: Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. *Br J Haematol*, 2020, 189, s. 869–878.
  - 62 Derenzini, E., et al.: MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. *Ann Oncol*, 2010, 21, s. 1173–1178.
  - 63 Montella, L., et al.: Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. *J Bone Miner Metab*, 2009, 27, s. 110–113.
  - 64 Ingram, W., et al.: Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans' cell histiocytosis and thrombocytopenia with absent radii. *Bone Marrow Transplant*, 2006, 37, s. 713–715.
  - 65 Pan, Y. – Xi, R. – Wang, C., et al.: Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk, BRAF V600E-negative Langerhans cell histiocytosis. *J Int Med Res*, 2019, 47, s. 4522–4529.
  - 66 Veys, P. A. – Nanduri, V. – Baker, K. S., et al.: Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. *Br J Haematol*, 2015, 169, s. 711–718.
  - 67 Cruz-Chacon, A. – Mathews, J. – Ayala, E.: Transplantation in rare lymphoproliferative and histiocytic disorders. *Cancer Control*, 2014, 21, s. 335–342.
  - 68 Gaundong Mbethe, G. L., et al.: Multifocal Langerhans cell histiocytosis of bone: indications for radiotherapy. *Cancer Radiother*, 2010, 14, s. 759–762.
  - 69 Brady, L. W., et al.: Langerhans cell histiocytosis. In: *Langerhans Cell Histiocytosis*. Olschewski, T. – Seegenschmied, M. H. – Mücke, O. (eds.), Springer Verlag, 2008, s. 397–423.
  - 70 Heyd, R., et al.: Radiotherapy in Langerhans-cell histiocytosis. 2 case reports and review of the literature. *Rontgenpraxis*, 2000, 53, s. 51–61.
  - 71 Micke, O. – Seegenschmied, M. H.: Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. *Int J Radiat Oncol Biol Phys*, 2002, 52, s. 496–513.
  - 72 Héritier, S. – Barkaoui, M. A. – Miron, J., et al.: Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. *Br J Haematol*, 2018, 183, s. 608–617.
  - 73 McClain, K. L. – Picarsic, J. – Chakraborty, R., et al.: CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. *Cancer*, 2018, 124, s. 2607–2620.
  - 74 Yeh, E. A. – Greenberg, J. – Abla, O., et al.: North American Consortium for Histiocytosis: Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. *Pediatr Blood Cancer*, 2018, 65.
  - 75 Keates-Baleeiro, J. – Rincon, M.: Morbid obesity as early manifestation of occult hypothalamic-pituitary LCH with delay in treatment. *Case Rep Oncol Med*, 2015, 2015, s. 915716.
  - 76 Imashuku, S. – Arceci, R. J.: Strategies for the prevention of central nervous system complications in patients with Langerhans cell histiocytosis: the problem of neurodegenerative syndrome. *Hematol Oncol Clin North Am*, 2015, 29, s. 875–893.
  - 77 Sieni, E. – Barba, C. – Mortilla, M., et al.: Early diagnosis and monitoring of neurodegenerative langerhans cell histiocytosis. *PLoS One*, 2015, 10, s. e0131635.
  - 78 Imashuku, S.: Commentary: Intravenous immunoglobulin (IVIg) therapy for patients with Langerhans cell histiocytosis (LCH)-related neurodegenerative diseases of the CNS. *CNS Neural Disord Drug Targets*, 2015, 14, s. 688–690.
  - 79 Imashuku, S. – Fujita, N. – Shioda, Y., et al.: Follow-up of pediatric patients treated by MIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. *Int J Hematol*, 2015, 101, s. 191–197.
  - 80 Novosad, O. – Skrypets, T. – Pastushenko, Y., et al.: MAPK/ERK signal pathway alterations in patients with Langerhans cell histiocytosis. *Klin Onkol*, 2018, 31, s. 130–134.
  - 81 Hyman, D. M. – Puzanov, I. – Subbiah, V., et al.: Vemurafenib in multiple nonmelanoma cancers with BRAFV600 mutations. *N Engl J Med*, 2015, 373, s. 726–736.
  - 82 Haroche, J. – Cohen-Aubart, F. – Emile, J. F., et al.: Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. *Blood*, 2013, 121, s. 1495–1500.
  - 83 Diamond, E. L. – Subbiah, V. – Lockhart, A. C., et al.: Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET Study. *JAMA Oncol*, 2018, 4, s. 384–388.
  - 84 Heisig, A. – Sörensen, J. – Zimmermann, S. Y., et al.: Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. *Oncotarget*, 2018, 9, s. 22236–22240.
  - 85 Charles, J. – Beani, J. C. – Fiandrino, G., et al.: Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. *J Am Acad Dermatol*, 2014, 71, s. e97–e99.
  - 86 Várdi, Z. – Bánusz, R. – Csomor, J., et al.: Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim-Chester disease. *Onco Targets Ther*, 2017, 10, s. 521–526.
  - 87 Héritier, S. – Jehanne, M. – Leverger, G., et al.: Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. *JAMA Oncol*, 2015, 1, s. 836–838.
  - 88 Haroche, J. – Cohen-Aubart, F. – Emile, J. F., et al.: Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. *J Am Acad Dermatol*, 2015, 73, s. e29–e30.
  - 89 Donadieu, J. – Larabi, I. A. – Tardieu, M., et al.: Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. *J Clin Oncol*, 2019, 37, s. 2857–2865.
  - 90 Kolenová, A. – Bubanská, E. – Špotová, A., et al.: Cílená léčba závažnej multisystémovej histiocytózy z Langerhansových buniek. *Pediatr Prax*, 2018, 19, s. 27–31.
  - 91 Oneal, P. A. – Kwitkowski, V. – Luo, L., et al.: FDA Approval Summary: Vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation. *Oncologist*, 2018, 23, s. 1520–1524.
  - 92 Cohen Aubart, F. – Emile, J. F. – Carrat, F., et al.: Targeted therapy in 54 patients with Erdheim-Chester disease, including follow up after interruption (the LOVE study). *Blood*, 2017, 130, s. 1377–1380.
  - 93 Al Bayati, A. – Plate, T. – Al Bayati, M., et al.: Dabrafenib and trametinib treatment for Erdheim-Chester disease with brain stem involvement. *Mayo Clin Proc Innov Qual Outcomes*, 2018, 2, s. 303–308.
  - 94 Stewart, J. R. – Murzaku, E. C. – Sode, T. T., et al.: Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib. *JAAD Case Rep*, 2017, 4, s. 95–97.
  - 95 Lorillon, G. – Mourah, S. – Vercellino, L., et al.: Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma. *Ann Oncol*, 2016, 27, s. 2305–2307.
  - 96 Szturz, P. – Řehák, Z. – Koukalová, R.: Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. *Nucl Med Biol*, 2012, 39, s. 429–436.
  - 97 Prabhu, M. – Raju, S. – Chakraborty, D., et al.: Spectrum of 18F-FDG uptake in bilateral lung parenchymal diseases on PET/CT. *Clin Nucl Med*, 2020, 45, s. e15–e19.
  - 98 Albano, D. – Bosio, G. – Giubbini, R., et al.: Role of (18F)-FDG PET/CT in patients affected by Langerhans cell histiocytosis. *Jpn J Radiol*, 2017, 35, s. 574–583.
  - 99 Garcia, J. R. – Riera, E. – Bassa, P., et al.: 18F-FDG PET/CT in follow-up evaluation in pediatric patients with Langerhans histiocytosis. *Rev Esp Med Nucl Imagen Mol*, 2017, 36, s. 325–328.
  - 100 Obert, J. – Vercellino, L. – Van Der Gucht, A., et al.: 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. *Eur J Nucl Med Mol Imaging*, 2017, 44, s. 598–610.
  - 101 Agarwal, K. K. – Seth, R. – Behra, A., et al.: 18F-Fluorodeoxyglucose PET/CT in Langerhans cell histiocytosis: spectrum of manifestations. *Jpn J Radiol*, 2016, 34, s. 267–276.
  - 102 Hansen, N. J. – Hankins, J. H.: Pulmonary langerhans cell histiocytosis: PET/CT for initial workup and treatment response evaluation. *Clin Nucl Med*, 2015, 40, s. 153–155.
  - 103 Lee, H. J. – Ahn, B. C. – Lee, S. W., et al.: The usefulness of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with Langerhans cell histiocytosis. *Ann Nucl Med*, 2012, 26, s. 730–737.